Everest Medicines (HKSE:01952) Net Margin % : -359.59% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Everest Medicines's Net Income for the six months ended in Dec. 2023 was HK$-460.3 Mil. Everest Medicines's Revenue for the six months ended in Dec. 2023 was HK$128.0 Mil. Therefore, Everest Medicines's net margin for the quarter that ended in Dec. 2023 was -359.59%.

The historical rank and industry rank for Everest Medicines's Net Margin % or its related term are showing as below:

HKSE:01952' s Net Margin % Range Over the Past 10 Years
Min: -1871428.79 Med: -1933.11 Max: -670.57
Current: -670.57

HKSE:01952's Net Margin % is ranked worse than
68.46% of 1024 companies
in the Biotechnology industry
Industry Median: -153.97 vs HKSE:01952: -670.57

Everest Medicines Net Margin % Historical Data

The historical data trend for Everest Medicines's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Net Margin % Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-1,871,428.79

-1,933.11

-670.57

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Margin %	Get a 7-Day Free Trial					-1,160,666.67	-63,976.88	3,581.58	-4,762.45	-359.59

Competitive Comparison of Everest Medicines's Net Margin %

For the Biotechnology subindustry, Everest Medicines's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Net Margin % distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Net Margin % falls into.

Everest Medicines Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Everest Medicines's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-923.656	/	137.742
	=	-670.57 %

Everest Medicines's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-460.318	/	128.013
	=	-359.59 %

Everest Medicines (HKSE:01952) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Everest Medicines Net Margin % Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines (HKSE:01952) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Ra Capital Management, L.p.	2102 Investment manager
Kolchinsky Peter	2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Fu Wei	2307 Founder of a discretionary trust who can infl
Janchor Partners Limited	2102 Investment manager
C-bridge Capital Gp, Ltd.	2501 Other
Vistra Trust (singapore) Pte. Limited	2501 Other
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited	2101 Beneficial owner

Everest Medicines (HKSE:01952) Headlines

No Headlines